Advances in Dermatology and Allergology
facebook
eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current Issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Ethical standards and procedures Reviewers Instructions for authors Publication charge
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
5/2017
vol. 34
 
Share:
Send email
Share:
abstract:
Review paper

Pregnancy: a therapeutic dilemma

Ligia Brzezińska-Wcisło
,
Martyna Zbiciak-Nylec
,
Dominika Wcisło-Dziadecka
,
Natalia Salwowska

Adv Dermatol Allergol 2017; XXXIV (5): 433–438
DOI: https://doi.org/10.5114/ada.2017.71108
Online publish date: 2017/10/31
View full text Get citation
 
Treatment during pregnancy is problematic. The Food and Drug Administration established drug categories to help in the treatment process. First-generation antihistamines are considered safe but they have sedative properties. Second-generation antihistamines cause less adverse reactions but besides cetirizine and loratadine they belong to category C. All retinoids should be avoided during pregnancy due to the risk of fetal malformations. Antimalarial drugs should be considered based on the clinical data. Sulfones can be considered as safe for use during pregnancy only with proper monitoring. Prednisone is administered in pregnancy. Other glucocorticosteroids have a different safety profile. Cyclosporine A treatment should be reserved as rescue therapy in severe stages of the disease. Treatment during pregnancy should be precise when it comes to pregnant woman and safe for the fetus.
keywords:

pregnancy, antihistamine, drug categories, retinoids, antimalarial drugs

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Termedia.